Debbie Becker

The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization

Michele Kohli, Michael Maschio, Debbie Becker et al. · Vaccine · 2021 · 151 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia*

Michael Drummond, Debbie Becker, Margaret Hux et al. · CHEST Journal · 2003 · 56 citations

Pharmacy, Infectious Diseases, Pharmacoeconomics +15

Impact of a health education intervention in overactive bladder patients.

Sender Herschorn, Debbie Becker, Elizabeth Miller et al. · PubMed · 2004 · 49 citations

Medicine, Health Education, Urology +17

Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial

Ayman Chit, Debbie Becker, Carlos A. DiazGranados et al. · The Lancet Infectious Diseases · 2015 · 47 citations

Veterinary Medicine, Geriatric Medicine, Pharmacoeconomics +12

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study

Ben Parker, Tom Ward, Olivia Hayward et al. · PLoS ONE · 2021 · 26 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17